This, it appears, is the research paper from 2011. 1R,2R,6S seems like a common compound (meaning the drug companies are not interested).
Any bio-chemists up on looking at this?

http://en.wikipedia.org/wiki/Carveol
An alpha-trans-dihydroxy derivative ((1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol) possesses potent antiparkinsonian activity in animal models.[3]

Volcho Konstantin: http://lib.bioinfo.pl/auid:18047424

http://pubs.acs.org/doi/full/10.1021/jm2001579#
Our study demonstrates that (1R,2R,6S)-1 displays a potent antiparkinsonian activity in vivo on models with MPTP in mice and rats and is not inferior to the reference agent (levodopa). Compound (1R,2R,6S)-1 clearly improves the markers of the locomotor and exploratory activities, thus removing the signs of the parkinsonian syndrome induced by neurotoxin injection. The described activity is proved by a number of tests with varying duration of toxin and agent administration (1–30 days).
Compound (1R,2R,6S)-1 almost completely prevents the development of catalepsy caused by haloperidol, which is demonstrated by a notable decrease in the catalepsy duration in animals, the duration of haloperidol time course, and the percent of cataleptic animals.
We synthesized all eight stereoisomers of compound 1 from the available monoterpenoids (+)- and (−)-α-pinenes and (+)- and (−)-carvones for the first time. According to our observations, the absolute configuration of compound 1 greatly influences its antiparkinsonian activity in the test with MPTP, from nearly full removal to a sharp increase in the symptoms of the parkinsonian syndrome.